Primary infiltrating signet ring carcinoma of the eyelids

A 61-year old man presented with a five-year history of a swelling initially developing in his right lower lid that progressed to involve the lateral canthal skin and eventually the upper lid and anterior orbit. He was discovered to have an infiltrating, poorly differentiated, mucin-producing carcinoma. Systemic work-up failed to disclose a visceral malignancy, and it was concluded that his tumor was primary in the lids, arising from an adnexal sweat gland. Three other reports in the literature also share almost identical clinical and pathologic features, in that all of the earlier reports dealt with middle-aged or elderly men who had diffusely indurated lids. Histopathologically, the tumor cells grow diffusely in a sclerotic stroma, and resemble the "histiocytoid" variant of metastatic breast carcinoma to the lids in women. Ultrastructural studies in our case point toward an apocrine origin, although earlier authors have favored an eccrine origin. Despite its indolent clinical course, the tumor is capable of producing regional and distant metastases on long-term follow-up. Complete local excision, possibly necessitating radical surgery, is probably the preferred method of treatment, but local radiotherapy may have a beneficial effect in retarding spread of the disease.     

A Merkel cell tumor of the eyelid

The Merkel cell is a distinctive nondendritic, nonkeratinocytic, epithelial clear cell believed to migrate from the neural crest to the epidermis and dermis, which is usually located in or near the basal layer of the epidermis and associated with nerve terminations. Merkel first described these cells in 1875 as "Tastzellen" occurring in the snout of a mole. They are believed to function as slowly adapting mechanoreceptors that mediate the sense of touch. Tumors arising from Merkel cells have been reported to occur on the head and neck area, the trunk, arms, and legs, and resemble a primary cutaneous lymphoma or cutaneous metastasis of a lymphoma or a carcinoma. Electron microscopy, to locate the characteristic membrane-bound, dense core neurosecretory granules, is needed for accurate diagnosis. These tumors must be treated aggressively to minimize the chance of local recurrence and nodal or visceral metastases. The authors present a case of Merkel cell tumor occurring on the eyelid. The clinical history, light and electron microscopic findings are shown.     

板蓝根醇沉物的药理作用

目的：观察板蓝根醇沉物与板蓝根颗粒剂的差异。方法：对比研究板蓝根醇沉物与板蓝根颗粒剂前浸膏的药理作用。结果：板蓝根醇沉物的热解、抗炎及抗茵作用与同剂量板蓝根颗粒剂前浸膏相同，其靛蓝含量高于板蓝根颗粒剂前浸膏。结论：板蓝根醇沉物有明显的解热、抗炎作用，板蓝根制剂传统制备工艺有待改进。     

尿石通颗粒中总黄酮的含量测定

目的:测定尿石通颗粒中总黄酮的含量。方法:用70％乙醇提取并制成供试品,采用分光光度法测定。结果:平均回收率为98.28％,RSD=2.13％。3批尿石通颗粒样品中总黄酮的含量分别为1.448,1.403,1.427 mg·g~(-1)。结论:本方法简便、准确、灵敏度高,可作为该制剂的质量控制方法。     

越桔冲剂对豚鼠支气管平滑肌收缩的影响

目的:研究越桔冲剂对正常及致敏豚鼠支气管平滑肌的影响。方法:通过实验,观察越桔冲剂对磷酸组织胺引起正常豚鼠支气管收缩的影响。结果:实验证明,越桔冲剂10ml·kg~(-1)对磷酸组织胺致正常豚鼠支气管收缩具有对抗作用(P<0.01)。结论:越桔冲剂具有显著的平喘作用。     

金叶败毒颗粒对孕鼠免疫和生殖功能影响的研究

目的 :探讨中药金叶败毒颗粒 (金银花、鱼腥草、大青叶等 )对孕鼠免疫功能的作用 ,以及其对孕鼠和子代发育安全性的影响。方法 :设试验组、空白组和阳性组 3组 ,给试验组孕鼠孕期持续灌服高剂量的金叶败毒颗粒 ,观察各组仔鼠骨骼、器官和染色体发育情况 ;分别测定孕鼠分娩前外周血免疫细胞数、腹腔巨噬细胞数、脾淋巴细胞激活实验和NK细胞活性。结果 :三组孕鼠一般情况和仔鼠发育无明显差异 ;试验组孕鼠外周血免疫细胞、腹腔巨噬细胞数明显增多 ,脾淋巴细胞A值和NK细胞活性明显高于两对照组 (P <0 .0 5)。结论 :金叶败毒颗粒对孕鼠及子代无毒副作用 ,能显著提高孕鼠免疫功能 ,可对孕期发生的生理性免疫功能降低起保护作用     

口腔愈疡颗粒质量标准的建立

目的：建立口腔愈疡颗粒的质量标准。方法：采用高效液相色谱法对成品中芍药苷进行含量测定。结果：芍药香浓度线性范围为：0．104—0．520μg/ml,γ=0.9993。样品平均回收率为98．85％，RSD为1．27％(n＝5)。结论：该方法适用于口腔愈疡颗粒的质量控制。     

HPLC法同时测定胃痛欣颗粒剂中大黄酸、大黄素、大黄酚的含量

目的建立胃痛欣颗粒剂中大黄酸、大黄素、大黄酚的含量测定方法。方法采用高效液相色谱法 ,AccusilC1 8(4 6mm× 2 5 0mm ,1 0 μm)柱 ,流动相为 :甲醇 水 冰醋酸 (80∶2 0∶1 ,V∶V∶V) ,检测波长为 2 5 4nm。结果大黄酸、大黄素、大黄酚分别在 0 0 3～ 0 4 8μg ,0 0 2 5～ 0 4 0 μg ,0 0 2 5～0 4 0 μg内与峰面积呈线性关系 ,平均回收率 (n =3 )分别为 98 3 % (RSD =1 4 3 % ) ,97 6% (RSD=1 84 ) ,98 7% (RSD =0 5 7% )。结论可用于大黄药材及其复方制剂的质量控制     

薄层扫描法测定更年康冲剂中丹参酮ⅡA的含量

目的:测定更年康冲剂中丹参酮ⅡA的含量.方法:采用双波长薄层扫描法.结果:丹参酮ⅡA的点样量为0.50～2.50 μg,与吸收度积分值呈良好的线性关系,平均回收率98.50%,RSD＝1.71%.结论:该方法简便、灵敏、重现性好.     

利巴韦林颗粒剂对小儿病毒性上呼吸道感染的疗效评价

[目的] 评价利巴韦林颗粒剂(同欣颗粒)对小儿病毒性上呼吸道感染的疗效和安全性。[方法] 将446例病毒性上呼吸道感染儿童随机分为同欣颗粒治疗组(1组)和利巴韦林注射剂(病毒唑注射液)治疗组(Ⅱ组)。Ⅰ组共有病例235例，每日3次口服同欣颗粒，用药剂量为10mg／(kg．d)；Ⅱ组为211例，每日2次肌肉注射病毒哩，剂量为10mg／(kg．d)。用χ2检验评定两组间在疗效和安全性方面的差异。[结果]Ⅰ组有194例为显效，显效率82．6％，不良反应发生率为4．7％；Ⅱ组显效人数为180例，显效率85．3％，不良反应发生率为5．2％。两组在疗效和不良反应方面无显著性差异，P＞0．05。[结论]同欣颗粒在用于治疗小儿病毒性上呼吸道感染时，与病毒唑注射液的疗效和安全性基本相同。